Alembic Pharmaceuticals Limited announced a significant milestone with the first prescription-based sale of Pivya® (pivmecillinam) tablets in the United States following its recent commercial launch. This achievement marks the company's entry into the US branded pharmaceuticals market through its step-down wholly owned subsidiary, Alembic Therapeutics LLC.

Product Overview and Market Position

Pivya® represents Alembic's first branded pharmaceutical product in the US market, positioning the company in the specialty prescription segment. The oral prescription antibiotic is indicated as a first-line treatment for uncomplicated urinary tract infections (uUTIs) in women, addressing a therapeutic area that has experienced limited new product introductions for more than a decade.

Therapeutic Significance and Market Context

Uncomplicated urinary tract infections remain among the most common bacterial infections in women in the US, resulting in significant outpatient antibiotic prescription volumes annually. The therapeutic category represents a substantial and stable market, accounting for approximately 30 million prescriptions annually in the US.

Pivya® contains pivmecillinam, a beta-lactam antibacterial agent with an established international clinical history. The penicillin-class antibacterial is specifically indicated for female patients 18 years of age and older with uncomplicated urinary tract infections caused by susceptible isolates of:

• Escherichia coli
• Proteus mirabilis
• Staphylococcus saprophyticus

Strategic Leadership Perspective

Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, emphasized the strategic importance of this milestone: "The commercial launch of Pivya® marks an important milestone for Alembic as we enter the US branded pharmaceuticals market. What began as a strategic acquisition has now translated into a commercial presence in the specialty prescription segment."

He further outlined the company's broader vision: "Pivya® represents the first step in Alembic's strategy to build a focused branded specialty portfolio in the US, enabling us to participate in a large and stable therapeutic category with a clinically established and differentiated product. Over time, we intend to leverage this platform to build a broader branded portfolio in the US market."

Commercial Strategy and Market Approach

Alembic has established an initial sales footprint across key territories in the US, with each territory focusing on high-prescribing physicians in women's health and engaging a targeted base of prescribers. The company plans a phased expansion of its field force as prescription momentum builds, supported by targeted physician education and market access initiatives.

The launch strategy emphasizes appropriate antibiotic stewardship and positions pivmecillinam as an important tool in managing uncomplicated urinary tract infections, particularly given the increasing emphasis on effective first-line therapies.

Strategic Context and Future Outlook

This development represents an important step in Alembic's broader US market strategy, which encompasses a balanced approach across generics, specialty products, and branded pharmaceuticals. The Pivya® launch establishes a branded business platform in the US that complements the company's established generics franchise.

Alembic continues its commitment to disciplined investments supporting sustainable growth and long-term value creation in one of the world's largest pharmaceutical markets. The company's vertically integrated research and development capabilities, combined with USFDA-approved manufacturing facilities, provide a strong foundation for this branded pharmaceuticals initiative.

Alembic Pharmaceuticals Limited has announced scheduled one-on-one investor meetings with major institutional investors, demonstrating the company's commitment to maintaining strong investor relations and transparency.

Meeting Details

The pharmaceutical company's management will conduct individual meetings with several prominent institutional investors on March 6, 2026 in Mumbai. These meetings represent an important aspect of the company's investor engagement strategy.

Participating Institutional Investors

The meetings will include representatives from five major institutional investors, reflecting significant interest from the investment community:

• HDFC Mutual Fund
• TATA AIA Life Insurance
• HDFC Life Insurance
• Birla Life Insurance
• ICICI Prudential Mutual Fund

Regulatory Compliance

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about these investor meetings as part of its disclosure obligations under Regulation 30. Company Secretary Manisha Saraf signed the notification on March 4, 2026, ensuring proper compliance with regulatory requirements.

Investor Engagement Significance

These one-on-one meetings provide an opportunity for institutional investors to engage directly with the company's management team. Such interactions typically allow for detailed discussions about business performance, strategic initiatives, and future prospects, facilitating better understanding between the company and its institutional stakeholders.